Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Glybera first gene therapy to gain EMA approval

By News team

Alipogene tiparvovec has become the first gene therapy to be recommended for approval by the European Medicines Agency.

The drug, branded Glybera by UniQure, is a solution for injection used for treating adults with lipoprotein lipase (LPL) deficiency, a genetic disorder that affects one or two people per million.

Current treatment for LPL deficiency involves restricting dietary fat to less than 20 per cent of daily calorie intake. Alipogene tiparvovec enables LPL production by delivering working copies of the gene to the muscle cells.

After rejecting two previous marketing authorisation applications for the drug, the EMA’s Committee for Medicinal Products for Human Use re-evaluated it and last week gave a positive opinion for its use in the treatment of patients with severe or multiple pancreatitis attacks, and with the requirement that patient outcomes data are shared with the EMA.

Rachel Airley, senior pharmacy lecturer at the University of Huddersfield, said Glybera’s approval is "an exciting and significant development in medicines research".

Dr Airley, who is a member of the Royal Pharmaceutical Society’s English Pharmacy Board, explained: "The discovery and development of genes as medicines has been a difficult process." Development of the technology might lead to treatments for a variety of diseases caused by faulty gene expression, including cystic fibrosis, she suggested.

The CHMP’s opinion on Glybera will now be sent to the European Commission for the adoption of a decision.

Citation: The Pharmaceutical Journal URI: 11104528

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • DNA  (Bobus/

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.